NanoViricides is a biotechnology business based in the US. NanoViricides shares (NNVC) are listed on the NYSE MKT and all prices are listed in US Dollars. NanoViricides employs 17 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $1.45 |
|---|---|
| 52-week range | $1.04 - $3.88 |
| 50-day moving average | $1.45 |
| 200-day moving average | $1.82 |
| Wall St. target price | $8.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.73 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.45 from 2023-01-26
| 1 week (2023-01-20) | 3.57% |
|---|---|
| 1 month (2022-12-27) | 28.32% |
| 3 months (2022-10-28) | -12.12% |
| 6 months (2022-07-28) | -20.33% |
| 1 year (2022-01-28) | -32.87% |
|---|---|
| 2 years (2021-01-28) | -61.33% |
| 3 years (2020-01-28) | 8.4 |
| 5 years (2018-01-26) | 46.42% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.37% |
| Return on equity TTM | -28.33% |
| Profit margin | 0% |
| Book value | $1.86 |
| Market capitalisation | $16.4 million |
TTM: trailing 12 months
We're not expecting NanoViricides to pay a dividend over the next 12 months.
NanoViricides's shares were split on a 1:20 basis on 23 September 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NanoViricides shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NanoViricides shares which in turn could have impacted NanoViricides's share price.
Over the last 12 months, NanoViricides's shares have ranged in value from as little as $1.04 up to $3.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while NanoViricides's is 1.068. This would suggest that NanoViricides's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NanoViricides, Inc. , a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
